The Cleveland Clinic, one of the best of the country and the most innovative hospitals, were today announced its list of the top 10 medical innovations that are likely to have a major impact on the improvement of patient care in the year 2015. Medical innovation year list was announced selected by a jury made up of 10 Cleveland Clinic physicians and scientists, and while their 2014 medical innovation Summit.
medical innovations by Cleveland Clinic for 2015
that economic success, (C) be available in 2015 on the market, and (d) considerable human interest in his application or benefits. On the basis of these criteria are the top 10 medical innovations for the year 2015:
1 Fast and Painless blood tests:
Improvement on the familiar needle and vial, a new device features a single drop of blood from the tip of a finger in a nearly painless process. This accelerated method is expected that reducing the cost of blood draws less than 10% of the current reimbursement by Medicare.
2 Dengue fever vaccine:
50 million people worldwide in more than 100 countries are (also known as “Breakbone fever”) patients every year with this mosquito-borne virus. A vaccine has been developed and tested, and is expected to end of 2015 market reach.
3 Mobile stroke units:
every second counts when a patient has suffered a stroke. The faster she diagnosed and treated is, the better the chances of recovery. To take advantage of the critical time when transporting a patient to the hospital, a mobile stroke unit is occupied, with a paramedic, intensive care nurse and one axial tomography (CT)-technologist, evaluating neurological function and managing Tissue plasminogen activator (t-PA), which assists in the breakdown of clots. In the meantime, tele-medicine can stroke neurologists in a hospital or other facility via broadband transmission specialist to consult.
4 PCSK9 inhibitor for cholesterol reduction:
For more than two decades doctors have cholesterol and his risk of heart disease associated with the class of prescription medications known as Statins reduced. Unfortunately some patients are intolerant and may not benefit from them. In the year 2015, the FDA should the first PCSK9 inhibitor, cholesterol an inject able drug for patients to approve that intolerant are stain.
5 Antibody drug conjugates:
Conventional chemotherapy was always a double-edged sword. It kills cancer cells, but at the same time injures or destroys healthy cells. A much-promising new approach to the in advanced tumor cells without collateral damage for normal, healthy tissue provides selective cytotoxic agents.
6 Autoimmune checkpoint inhibitors:
In combination with chemotherapy and/or radiation, this can strengthen newly developed drugs significantly increasing the immune system and the duration of remission of metastatic melanoma. Research continues to the drugs efficacy in the treatment of other cancers as well as determine.
7 Improved pacemaker:
Artificial pacemaker surgically inserted in many heart patients over the last fifty years, to regulate her heartbeat. The design remained essentially the same with a pulse generator, transmission of electronic power to the heart of small wires, inserted into a vein. But faulty or damaged pipes lead to infections in 2% of cases. To eliminate this danger, new pacemakers were developed to be inserted directly into the heart itself. They are much smaller (about the size of a medicine capsule) and can be implanted using minimally invasive surgery.
8 New drugs for idiopathic pulmonary fibrosis (IPF):
From the air sacs, scarring impairs lung function in this deadly condition. Without treatment, the life expectancy on 3-5 is limited to the years. by 2015, it is expected that FDA approval of Pirfenidone and Nintedanib, two drugs, see the the first treatments for IPF.
9 Single Dose intraoperative radiotherapy (IORT) in breast cancer:
Early detection and treatment of breast cancer saves lives. In early-stage breast cancer is that the treatment usually made a Lumpectomy and weeks of following radiotherapy. The surgical removal of the nodes in a dose of radiation is delivered with IORT.
10 New drug for congestive heart failure:
The FDA granted fast track designation to approve angioplasty receptor Neprilysin inhibitor (ARNI). ARNI has shown a significant increase in the survival rate of patients with congestive heart failure compared with the current standard drugs, which ACE inhibitors Enalapril-treated.
For feedback join us:
Email: [email protected]
